To investigate the effect of verapamil combined with deacetylflorin injection on coronary heart disease with rapid atrial fibrillation complicated by acute heart failure.

A total of 112 patients with coronary heart disease with rapid atrial fibrillation complicated by acute heart failure were selected from Jiaozhou People's Hospital from March of 2016 to December of 2017 were selected and randomly divided into experimental group (56 cases) and control group (56 cases). On the basis of routine treatment, the control group was treated with deacetylflorin injection, while the experimental group was treated with verapamil combined with deacetylflorin injection. After 3 days of treatment, the clinical effect, incidence of adverse reactions, heart rate, diastolic blood pressure and systolic blood pressure before and after treatment were compared between the two groups.

After 3 days of treatment, the total effective rate (96.43%) of the experimental group was higher than that of the control group (78.57%) (P<0.05); the heart rate, diastolic blood pressure and systolic blood pressure of experimental group were lower than those of control group (P<0.05). The incidence of adverse reactions of the experimental group (10.71%) was not significantly different from that of the control group (5.36%) (P>0.05).

Verapamil combined with deacetylflorin injection is effective in the treatment of patients with coronary heart disease with rapid atrial fibrillation complicated by acute heart failure. It can improve the heart rate and blood pressure of patients with high safety.